215 related articles for article (PubMed ID: 38528991)
21. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: The predicted hyper responder.
Oudshoorn SC; van Tilborg TC; Eijkemans MJC; Oosterhuis GJE; Friederich J; van Hooff MHA; van Santbrink EJP; Brinkhuis EA; Smeenk JMJ; Kwee J; de Koning CH; Groen H; Lambalk CB; Mol BWJ; Broekmans FJM; Torrance HL;
Hum Reprod; 2017 Dec; 32(12):2506-2514. PubMed ID: 29121269
[TBL] [Abstract][Full Text] [Related]
22. Live birth rates following individualized dosing algorithm of follitropin delta in a long GnRH agonist protocol.
Sánchez MF; Larsson P; Serrano MF; Bosch E; Velasco JAG; López ES; Mannaerts B
Reprod Biol Endocrinol; 2023 May; 21(1):45. PubMed ID: 37194068
[TBL] [Abstract][Full Text] [Related]
23. Oral medications including clomiphene citrate or aromatase inhibitors with gonadotropins for controlled ovarian stimulation in women undergoing in vitro fertilisation.
Kamath MS; Maheshwari A; Bhattacharya S; Lor KY; Gibreel A
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD008528. PubMed ID: 29096046
[TBL] [Abstract][Full Text] [Related]
24. Progestogens for prevention of luteinising hormone (LH) surge in women undergoing controlled ovarian hyperstimulation as part of an assisted reproductive technology (ART) cycle.
Glujovsky D; Pesce R; Miguens M; Sueldo C; Ciapponi A
Cochrane Database Syst Rev; 2023 Nov; 11(11):CD013827. PubMed ID: 38032057
[TBL] [Abstract][Full Text] [Related]
25. Randomized, assessor-blind, antimüllerian hormone-stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta.
Ishihara O; Klein BM; Arce JC;
Fertil Steril; 2021 Jun; 115(6):1478-1486. PubMed ID: 33272623
[TBL] [Abstract][Full Text] [Related]
26. Clinical outcomes of potential high responders after individualized FSH dosing based on anti-Müllerian hormone and body weight.
Višnová H; Papaleo E; Martin FS; Koziol K; Klein BM; Mannaerts B
Reprod Biomed Online; 2021 Dec; 43(6):1019-1026. PubMed ID: 34756645
[TBL] [Abstract][Full Text] [Related]
27. Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome.
D'Angelo A; Amso NN; Hassan R
Cochrane Database Syst Rev; 2017 May; 5(5):CD002811. PubMed ID: 28535578
[TBL] [Abstract][Full Text] [Related]
28. Long-acting FSH versus daily FSH for women undergoing assisted reproduction.
Pouwer AW; Farquhar C; Kremer JA
Cochrane Database Syst Rev; 2015 Jul; 2015(7):CD009577. PubMed ID: 26171903
[TBL] [Abstract][Full Text] [Related]
29. Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI).
Lensen SF; Wilkinson J; Leijdekkers JA; La Marca A; Mol BWJ; Marjoribanks J; Torrance H; Broekmans FJ
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD012693. PubMed ID: 29388198
[TBL] [Abstract][Full Text] [Related]
30. What is the optimal GnRH antagonist protocol for ovarian stimulation during ART treatment? A systematic review and network meta-analysis.
Venetis CA; Storr A; Chua SJ; Mol BW; Longobardi S; Yin X; D'Hooghe T
Hum Reprod Update; 2023 May; 29(3):307-326. PubMed ID: 36594696
[TBL] [Abstract][Full Text] [Related]
31. In vitro fertilization and multiple pregnancies: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2006; 6(18):1-63. PubMed ID: 23074488
[TBL] [Abstract][Full Text] [Related]
32. Volume expanders for the prevention of ovarian hyperstimulation syndrome.
Youssef MA; Mourad S
Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD001302. PubMed ID: 27577848
[TBL] [Abstract][Full Text] [Related]
33. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Do G; Hua C; Mazaud C; Droitcourt C; Hughes C; Ingram JR; Naldi L; Chosidow O; Le Cleach L
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011535. PubMed ID: 29271481
[TBL] [Abstract][Full Text] [Related]
34. A multicenter, randomized, phase III study comparing the efficacy and safety of follitropin alpha biosimilar and the original follitropin alpha.
Barakhoeva Z; Vovk L; Fetisova Y; Marilova N; Ovchinnikova M; Tischenko M; Scherbatyuk Y; Kolotovkina A; Miskun A; Kasyanova G; Teterina T; Zorina I; Belousova N; Morozova E; Yakovenko S; Apryshko V; Sichinava L; Shalinа R; Polzikov M
Eur J Obstet Gynecol Reprod Biol; 2019 Oct; 241():6-12. PubMed ID: 31400644
[TBL] [Abstract][Full Text] [Related]
35. Prospective multicenter non-interventional real-world study to assess the patterns of use, effectiveness and safety of follitropin delta in routine clinical practice (the PROFILE study).
Blockeel C; Griesinger G; Rago R; Larsson P; Sonderegger YLY; Rivière S; Laven JSE
Front Endocrinol (Lausanne); 2022; 13():992677. PubMed ID: 36619578
[TBL] [Abstract][Full Text] [Related]
36. Dopamine agonists for preventing ovarian hyperstimulation syndrome.
Tang H; Mourad S; Zhai SD; Hart RJ
Cochrane Database Syst Rev; 2016 Nov; 11(11):CD008605. PubMed ID: 27901279
[TBL] [Abstract][Full Text] [Related]
37. Updated meta-analysis of recombinant follicle-stimulating hormone (FSH) versus urinary FSH for ovarian stimulation in assisted reproduction.
Daya S
Fertil Steril; 2002 Apr; 77(4):711-4. PubMed ID: 11937121
[TBL] [Abstract][Full Text] [Related]
38. FSH replaced by low-dose hCG in the late follicular phase versus continued FSH for assisted reproductive techniques.
Martins WP; Vieira AD; Figueiredo JB; Nastri CO
Cochrane Database Syst Rev; 2013 Mar; (3):CD010042. PubMed ID: 23543584
[TBL] [Abstract][Full Text] [Related]
39. Patient and nurse evaluation of recombinant human follicle-stimulating hormone administration methods: comparison of two follitropin injection pens.
Porter R; Kissel C; Saunders H; Keck C
Curr Med Res Opin; 2008 Mar; 24(3):727-35. PubMed ID: 18230195
[TBL] [Abstract][Full Text] [Related]
40. [Pharmacological profile, clinical efficacy, and safety of Follitropin Delta produced by recombinant DNA technology in a human cell line (REKOVELLE
Abe Y; Ozeki Y
Nihon Yakurigaku Zasshi; 2022; 157(1):76-84. PubMed ID: 34980816
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
